zŠÂŠí“à‰ÈŠwuÀ –ß‚é
Department of Cardiovascular Medicine
•”@–å ‘‡ˆã–ò‰ÈŠw•”–å
•ª@–ì ‘ãŽÓEzŠÂˆãŠw•ª–ì
ƒz[ƒ€ƒy[ƒW http://www.kumadai-junnai.com/
ƒX
ƒ^
ƒb
ƒt
‹³Žö ’Ò“c@Œ«ˆê
y‹³Žö ŠC–k@Kˆê
uŽt â–{@Œ›Ž¡i‘åŠw•a‰@Š‘®j
•‹³ ŽR–{@‰pˆê˜Yi‘åŠw•a‰@Š‘®j
•‹³ ûü’ª@ªŽ¢i‘åŠw•a‰@Š‘®j
•‹³ —L”n@—Eˆê˜Y
•‹³ r–؁@’q
Œ¤‹†ƒe[ƒ}
yŒ¤‹†ƒvƒƒWƒFƒNƒg–¼‚¨‚æ‚ÑŠT—vz
  1. ‹}«Š¥ÇŒóŒQ‚Ì”­¶‹@˜A•a‘Ô‚È‚ç‚Ñ‚ÉŽ¡—ÂɊւ·‚錤‹†
  2. Š¥¹k«‹·SÇ‚Ì”­¶‹@˜A•a‘Ô‚È‚ç‚Ñ‚ÉŽ¡—ÂɊւ·‚錤‹†
  3. S•s‘S‚Ì•aˆöE•a‘Ô‚ÌŒ¤‹†‚Æ‚»‚ê‚ÉŠî‚¢‚½Ž¡—Ö@‚ÌŠJ”­
  4. SŒŒŠÇŽ¾Š³‚É‚¨‚¯‚錌ŠÇ“à”ç‹@”\‚̗Տ°“I•]‰¿‚ÆŒŒŠÇ“à”ç×–EáŠQƒ}[ƒJ[‚ÉŠÖ‚·‚錤‹†
  5. zŠÂŠíŽ¾Š³‚É‚¨‚¯‚é’¼Ú“IŒoŒûR‹ÃŒÅ–ò‚̐V‹Kƒ‚ƒjƒ^ƒŠƒ“ƒOƒVƒXƒeƒ€‚ÌŠm—§
  6. Ž•Žü•aAŠ´õÇ‚ÆŠ¥“®–¬Ž¾Š³‚ÌŠÖ˜A‚ɂ‚¢‚Ă̗Տ°Œ¤‹†
  7. SŒŒŠÇŽ¾Š³‚Ì•aˆöE•a‘Ô‚É‚¨‚¯‚éŽ_‰»ƒXƒgƒŒƒX‚Ì–ðŠ„‚É‚Â‚¢‚Ă̗Տ°“IŒŸ“¢
  8. œŠi‹Ø‚æ‚蕪”傳‚ê‚éV‹KSŒŒŠÇ•ÛŒìˆöŽq‚Ì“¯’è‚Æ‚»‚Ì‹@”\‰ðÍ
  9. ‹•ŒŒ«SŽ¾Š³Š³ŽÒ‚É‚¨‚¯‚é‹}«Šú‹y‚Ñ–«ŠúS‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚ÆŠñ—^ˆöŽq‚ɂ‚¢‚Ä‚ÌŒ¤‹†
  10. The PRECISE-IVUS trial (Plaque Regression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound) Š¥“®–¬ƒvƒ‰[ƒN‘ޏk‚É‚¨‚¯‚éƒRƒŒƒXƒeƒ[ƒ‹‹zŽû‘jŠQ–ò‚¨‚æ‚э‡¬‘jŠQ–ò‚ÌŒø‰Ê|ŒŒŠÇ“à’´‰¹”g‚ð—p‚¢‚½ŒŸ“¢|
  11. CALDERA-GENE Study (Controlled Anti-pLatelet meDical thErapy based on RApid CYP2C19 GENe Evaluation in myocardial infarction) ‹}«S‹Ø[Ç‚É‚¨‚¯‚éCYP2C19‹@”\‘rŽ¸ˆâ“`Žq‚̐v‘¬ŒŸo‚ÆŽŠ“K–ò•¨Ž¡—Ö@‚ÌŠm—§
  12. INVITATION trial (Dose-Dependent INhibitory Effect of RosuVastatin In Japanese Patients with Acute Myocardial InfarcTION on Serum Concentration of Matrix Metalloproteinase) ‹}«S‹Ø[ÇŠ³ŽÒ‚ð‘ΏۂƂµ‚½‰ŠÇƒ}[ƒJ[MMPs‚ɑ΂·‚郍ƒXƒoƒXƒ^ƒ`ƒ“‚Ì—p—Ê”äŠrŽŽŒ±

@‹}«Š¥ÇŒóŒQ‚Í“®–¬d‰»«Š¥“®–¬ƒvƒ‰[ƒN‚Ì”j’]‚Ɉø‚«‘±‚«Š¥“®–¬“àŒŒð‚ª¶‚¶‚邱‚Æ‚É‚æ‚è”­Ç‚·‚éB‰äX‚Í‚±‚ê‚Ü‚Å‹}«Š¥ÇŒóŒQ(ACS)‚Ì•a‘Ô‚ðAƒvƒ‰[ƒN”j’]‚̈ø‚«‹à‚ƂȂ銥“®–¬¹k‚̃ƒJƒjƒYƒ€‚Ì’T‹†‚ƁAƒvƒ‰[ƒN”j’]Œã‚ÌŒŒðŒ`¬‚ÉŠÖ—^‚·‚é‹ÃŒŒŠw“I‚È•ªŽqƒ}[ƒJ[‚Ì“®‘Ô‚ðŒŸ“¢‚·‚邱‚Æ‚É‚æ‚è‰ð–¾‚µ‚Ä‚«‚½BŒ»ÝAŠ¥“®–¬ƒvƒ‰[ƒNŒ`¬‚ÉŽŠ‚镪Žq¶•¨Šw“IƒƒJƒjƒYƒ€‚̉𖾂âA‘½Ž{Ý‘å‹K–͗Տ°ŽŽŒ±‚É‚æ‚éACS”­Ç—\–h‚Ì–ò•¨ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“‚ɂ‚¢‚Ä‚àŒŸ“¢‚ði‚ß‚Ä‚¢‚éB
@‚Ü‚½ŠJ‹¹Žèp‚ª¢“ï‚ȏdÇ‘å“®–¬•Ù‹·óÇŠ³ŽÒ‚³‚ñ‚Ö‚ÌŒoƒJƒe[ƒeƒ‹‘å“®–¬•ÙA‚¦ž‚ݏp(TAVI)‚à“K‰ž‚ðÚ×‚ÉŒŸ“¢‚µŽ{s‚µAŒ»Ý‚܂ŘA‘±85Œ‚̏Ǘá‚𐬌÷‚µ‚Ä‚¢‚éB @‚Ü‚½A•a‘ÔƒƒJƒjƒYƒ€‚̉𖾁EV‹KŽ¡—Ö@‚Ì’Tõ‚Ì‚½‚߁AS•s‘SES‹Ø[ÇE‰ºŽˆ‹•ŒŒ‚Ȃǂ̏zŠÂŠíŽ¾Š³ƒ‚ƒfƒ‹‚̉ðÍ‚âA×–E“àƒ^ƒ“ƒpƒN‚̈â“`Žq‰ü•Ï“®•¨‚ð—p‚¢‚½Šî‘bŒ¤‹†‚ài‚ß‚Ä‚¢‚éB

ŒF–{‘åŠw•a‰@@ƒnƒCƒuƒŠƒbƒhŽèpŽº
Hybrid operation room at Kumamoto University Hospital


Acute coronary syndrome (ACS) such as acute myocardial infarction, unstable angina, ischemic sudden death is recognized as pathological conditions caused by intracoronary thrombus formation following atherosclerotic coronary plaque rupture. We have elucidated the roles of coronary spasm and the blood coagulation and fibrinolytic systems in onset and progression of ACS.
Since 2015, we successfully introduced transcatheter aortic valve implantation (TAVI) procedure to consecutive 85 patients with severe aortic valve stenosis who could not have a surgical aortic valve replacement because of high age and comorbidities.
We also actively work on basic researches to elucidate the etiologies cardiovascular diseases, using animal models genetically engineered mice.


@